Patents Examined by Michael Borin
-
Patent number: 9563266Abstract: The present technology relates to systems, methods and devices for haptically-enabled virtual reality simulation of cerebral aneurysm clipping, wherein a user uses two physical stations during the simulation. The first station is a haptic and augmented reality station, and the second station is a haptic and virtual reality station.Type: GrantFiled: September 27, 2012Date of Patent: February 7, 2017Assignees: IMMERSIVETOUCH, INC., THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOISInventors: P. Pat Banerjee, Cristian J. Luciano
-
Patent number: 9552457Abstract: Methods of “reprogramming” epigenetic mark readers or erasers to recognize epigenetic marks other than their cognate (or natural) marks are provided. Reprogramming the reader or eraser can offset the effects of aberrant writer activity (for example, loss of function or overactivity) that can contribute to certain diseases states, such as cancer. The use of the reprogramming compounds identified by these methods in the treatment of such disease states is also provided. Exemplary mark readers that can be targeted by these methods include BPTF and CBX2.Type: GrantFiled: February 27, 2013Date of Patent: January 24, 2017Assignee: BRITISH COLUMBIA CANCER AGENCY BRANCHInventors: Steven J. M. Jones, Oleksandr Yakovenko, Silvia Thoene, Pierre Yulmin Cheung, Jianghong An
-
Patent number: 9495517Abstract: Cell-bound complement activation product (CB-CAP) profiling and scoring serve as diagnostic biomarkers for patients to determine whether a patient who has not met at least four American College of Rheumatology (or similar e.g. SLICC) criteria for a definite Lupus diagnosis should be classified as exhibiting a pre-existing condition that this document refers to as pre-Lupus.Type: GrantFiled: August 6, 2015Date of Patent: November 15, 2016Assignee: Allegheny-Singer Research InstituteInventors: Joseph M. Ahearn, Chau-Ching Liu, Susan M. Manzi
-
Patent number: 9454642Abstract: The present invention provides a prediction device, a prediction method, a program, and a recording medium, with which whether or not desired aptamer sequences are enriched can be predicted easily. The prediction device of the present invention 10 includes an input unit 11, a calculation unit 12, and a prediction unit 13. The input unit 11 is a unit through which sequence information on a target aptamer sequence group including selected aptamers in a target pool and a reference aptamer sequence group including reference aptamer sequences are inputted. The calculation unit 12 calculates the free energy of the target aptamer sequence group and the free energy of the reference aptamer sequence group. The prediction unit 13 compares the free energy of these sequence groups, and predicts that the target pool is an enriched pool when the free energy of the target aptamer sequence group is lower than the free energy of the reference aptamer sequence group.Type: GrantFiled: July 2, 2011Date of Patent: September 27, 2016Assignees: NEC Solution Innovators, Ltd., KANAGAWA PREFECTURAL HOSPITAL ORGANIZATIONInventors: Jou Akitomi, Shintarou Katou, Shotaro Tsuji, Iwao Waga
-
Patent number: 9451886Abstract: A probabilistic digital signal processor using data from multiple instruments is described. In one example, an analyzer is configured to: receive discrete first and second input data, related to a first and second sub-system of the system, from a first and second instrument, respectively. A system processor is used to fuse the first and second input data into fused data. The system processor optionally includes: (1) a probabilistic processor configured to convert the fused data into at least two probability distribution functions and (2) a dynamic state-space model, the dynamic state-space model including at least one probabilistic model configured to operate on the at least two probability distribution functions. The system processor iteratively circulates the at least two probability distribution functions in the dynamic state-space model in synchronization with receipt of updated input data, processes the probability distribution functions, and generates an output related to the state of the system.Type: GrantFiled: July 12, 2011Date of Patent: September 27, 2016Inventor: Rodrigo E. Teixeira
-
Patent number: 9345418Abstract: An electroencephalography system is provided. The electroencephalography system includes a support structure that covers at least predetermined areas on a patient's head, a plurality of electrodes mounted on the support structure so that, the electrodes are distributed around the patient's head and measure usable electrical signals that are representative of electrical activity or activity in a patient's head, a plurality of transmitting wires incorporated into the support structure, a multi-pin connector having an output and an input, each of the plurality of transmitting wires directly connected between a respective one of each of the plurality of electrodes and a corresponding pin of the multi-pin connector so that, electrical signals are sent to the output of the connector and a first transmitter that is capable of being operatively coupled to the output of the connector.Type: GrantFiled: March 27, 2008Date of Patent: May 24, 2016Assignee: Dignity HealthInventor: Brian Alkire
-
Patent number: 9334494Abstract: The present invention provides a method of selecting a mRNA for production of a polypeptide of interest comprising: a) producing an array of individual mRNA sequences comprising different nucleotide sequences encoding the polypeptide of interest; b) determining one or more or two or more of the following parameters for each individual mRNA sequence of (a): (i) minimum free energy (MFE) RNA secondary structure; (ii) ensemble free energy (EFE); (iii) frequency of the minimum free energy (FMFE) RNA secondary structure in a thermodynamic ensemble; and (iv) ensemble diversity (ED); c) ranking the individual mRNA sequences of the array according the parameters determined in step (b); and d) selecting a mRNA sequence from the ranked array of step (c), wherein the selected mRNA produces the polypeptide of interest. The present invention further provides a method of selecting a mRNA for enhanced and reduced production of a polypeptide of interest.Type: GrantFiled: December 7, 2012Date of Patent: May 10, 2016Assignee: SYNGENTA PARTICIPATIONS AGInventors: Shib Sankar Basu, Kristen Kamerath Dang, Kasimalai Azhakanandam, Thomas Z. McNeill, Sheng Guo
-
Patent number: 9316636Abstract: A method of determining kinetic parameters for a reversible molecular interaction between a ligand immobilized to a solid support surface and a binding partner to the ligand in solution, comprises sequentially, without intermediate regeneration or renewal of the immobilized ligand, flowing a plurality of fluid volumes containing different known concentrations of the binding partner over the solid support surface, monitoring the momentary amount of binding partner bound to the solid support surface related to time and solution concentration of binding partner and collecting the binding data, and determining the kinetic parameters by globally fitting a predetermined kinetic model for the interaction between the binding partner and the immobilized ligand to the collected binding data, which model allows for mass transport limitation at the solid support surface.Type: GrantFiled: October 25, 2012Date of Patent: April 19, 2016Assignee: GE HEALTHCARE BIO-SCIENCES ABInventors: Robert Karlsson, Karl Andersson, Christina Wass
-
Patent number: 9289144Abstract: A method includes storing in memory preoperative brain atlas data. Neurophysiological data is obtained intra-operatively for a plurality of known sites in a brain of a given patient to provide corresponding intra-operative neurophysiological data for at least a portion of the sites. A constrained optimization is performed to fit the pre-operative brain atlas data based at least in part on the intra-operative neurophysiological data.Type: GrantFiled: November 6, 2008Date of Patent: March 22, 2016Assignee: THE CLEVELAND CLINIC FOUNDATIONInventors: J. Luis Lujan, Cameron C. McIntyre
-
Patent number: 9278159Abstract: The present invention provides compositions and methods for light-activated cation channel proteins and their uses within cell membranes and subcellular regions. The invention provides for proteins, nucleic acids, vectors and methods for genetically targeted expression of light-activated cation channels to specific cells or defined cell populations. In particular the invention provides millisecond-timescale temporal control of cation channels using moderate light intensities in cells, cell lines, transgenic animals, and humans. The invention provides for optically generating electrical spikes in nerve cells and other excitable cells useful for driving neuronal networks, drug screening, and therapy.Type: GrantFiled: July 24, 2006Date of Patent: March 8, 2016Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Karl Deisseroth, Edward S. Boyden
-
Patent number: 9262582Abstract: A method for the early prediction of risk of hypertensive disorders in pregnant women, including for example eclampsia, mild pre-eclampsia, chronic hypertension, EPH gestosis, gestational hypertension, superimposed pre-eclampsia, HELLP syndrome, or nephropathy.Type: GrantFiled: December 21, 2010Date of Patent: February 16, 2016Assignee: University College Cork, National University of Ireland, CorkInventors: Louise Kenny, Philip Newton Baker, David Broadhurst
-
Patent number: 9195795Abstract: A method for analysis, control, and manipulation for improvement of the chemical reaction rate of a protein-mediated reaction is provided. Enzymes, which typically comprise protein molecules, are very efficient catalysts that enhance chemical reaction rates by many orders of magnitude. Enzymes are widely used for a number of functions in chemical, biochemical, pharmaceutical, and other purposes. The method identifies key protein vibration modes that control the chemical reaction rate of the protein-mediated reaction, providing identification of the factors that enable the enzymes to achieve the high rate of reaction enhancement. By controlling these factors, the function of enzymes may be modulated, i.e., the activity can either be increased for faster enzyme reaction or it can be decreased when a slower enzyme is desired.Type: GrantFiled: April 14, 2011Date of Patent: November 24, 2015Assignee: UT-BATTELLE, LLCInventor: Pratul K. Agarwal
-
Patent number: 9140699Abstract: The invention relates to an analytical measuring and evaluation method for determining the interaction parameters between an analyte and a ligand, preferably in a biosensor. According to the inventive method, the concentration of the analyte is gradually changed at defined intervals ti and the initial association or dissociation rates or association and dissociation rate constants are determined. The invention further relates to a device for carrying out the inventive method.Type: GrantFiled: September 28, 2010Date of Patent: September 22, 2015Assignee: GE HEALTHCARE BIO-SCIENCES ABInventor: Hans-Heinrich Trutnau
-
Patent number: 9081736Abstract: This invention relates to representations of prostaglandin synthase three-dimensional structures. Such representations are suitable for designing agents that modulate the activity of the enzyme by binding to the substrate binding domain.Type: GrantFiled: April 1, 2011Date of Patent: July 14, 2015Assignee: The University of Kentucky Research FoundationInventors: Chang-Guo Zhan, Xiaoqin Huang, Adel Hamza
-
Patent number: 9002656Abstract: A computer-based method for automatically determining total body albumin of a living being based on the calculated intravascular albumin, the calculated observed ratio of amount of albumin in the intravascular system to amount of albumin in the extravascular system at the first time, and the baseline of expected ratio of amount of albumin in the intravascular system to amount of albumin in the extravascular system at the first time.Type: GrantFiled: October 17, 2011Date of Patent: April 7, 2015Assignee: Daxor CorporationInventors: Joseph Feldschuh, Jonathan Feldschuh
-
Patent number: 9002657Abstract: A computer-based method for automatically determining total body albumin of a living being based on the calculated intravascular albumin, the calculated observed ratio of amount of albumin in the intravascular system to amount of albumin in the extravascular system at the first time, and the baseline of expected ratio of amount of albumin in the intravascular system to amount of albumin in the extravascular system at the first time.Type: GrantFiled: March 9, 2012Date of Patent: April 7, 2015Assignee: Daxor CorporationInventors: Joseph Feldschuh, Jonathan Feldschuh
-
Patent number: 8972198Abstract: Methods of determining analyte concentration. The methods use a fraction of the predicted total charge, from analyte electrolysis, instead of using time, for determination of a data collection endpoint. The total charge is then extrapolated from the data collection endpoint. The analyte concentration is determined from the total charge.Type: GrantFiled: May 11, 2011Date of Patent: March 3, 2015Assignee: Abbott Diabetes Care Inc.Inventors: Ting Chen, Benjamin J. Feldman
-
Patent number: 8972196Abstract: Disclosed are embodiments that relate to algorithms and methods for calibrating an analyte sensor, and more particularly, to algorithms for calibrating an optical glucose sensor comprising an equilibrium fluorescent chemical indicator system. In particular, a method of detecting an analyte concentration is disclosed where a modified Michaelis-Menten equation comprising Michaelis-Menten parameters is used to characterize the signal generated by the analyte sensor.Type: GrantFiled: June 4, 2010Date of Patent: March 3, 2015Assignee: Medtronic Minimed, Inc.Inventors: Thomas A. Peyser, Soya Gamsey, Matthew A. Romey, David R. Markle
-
Patent number: 8898047Abstract: The invention concerns the generation of a three dimensional model of the six helix bundle (6HB) complexed with an inhibitor and the use of that model to identify, screen and/or develop inhibitors against viruses that use a class I fusion protein. Such inhibitors of viruses that use a class I fusion protein may be effective for treating, for example, respiratory infections by Respiratory Syncytial Virus (RSV).Type: GrantFiled: February 26, 2009Date of Patent: November 25, 2014Assignee: Janssen Pharmaceuticals NVInventors: Dirk André Emmy Roymans, Hendrik Leon Augusta Jozef De Bondt, Eric Pierre Alexandre Arnoult, Herman Van Vlijmen, Jean-François Bonfanti
-
Patent number: 8892364Abstract: The invention is based, at least in part, on the development of stabilized binding molecules that consist of or comprise a stabilized scFv and methods for making such stabilized molecules.Type: GrantFiled: August 17, 2007Date of Patent: November 18, 2014Assignee: Biogen Idec MA Inc.Inventors: Scott Glaser, Stephen Demarest, Brian Robert Miller, William B. Snyder, Xiufeng Wu, Norman Wang, Lisa J. Croner, Alexey Alexandrovich Lugovskoy